The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ErratumFull Access

Erratum

The July 15 Med Check column incorrectly reported that a study on atomoxetine (Strattera) by Humberto Quintana, M.D., of Louisiana State University found that children given the drug as a once-a-day evening dose were more likely to report adverse events than children taking the medication as a once-a-day morning dose. The study found the opposite: the percentage of children experiencing at least one adverse event was 74 percent with morning dosing, 48.9 percent with evening dosing, and 43.5 percent with placebo.▪